Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial Hypertension
The primary aim of this study was to evaluate exercise capacity, respiratory muscle strength, pulmonary function, dyspnea and physical activity levels in pediatric PAH patients and compare them with healthy controls.
- Trial name
- NCT05124015
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gazi University
Pulmonary Arterial Hypertension
PET/MRI in PAH Patients
Aim of the study is to compare novel parameters of right ventricle (RV) function from right heart catheterization (RHC) and magnetic resonance imaging (MRI) with PET-derived RV FDG uptake.
- Trial name
- NCT03688698
- Testing
- PET/MRI
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are severe clinical conditions that, despite advances in therapeutics over the past 20 years, lead to serious morbidity and…
- Trial name
- NCT05618093
- Testing
- Non-invasive hemodynamic measurements
- Where
- United States
- Sponsor
- University of California, Los Angeles
Pulmonary Arterial Hypertension
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III.
- Trial name
- NCT05934526
- Testing
- Seralutinib, Generic Dry Powder Inhaler
- Where
- 166 sites in United States, Argentina and 29 more
- Volunteers
- 390 people
- Sponsor
- GB002, Inc.
Oxygen Deficiency, Pulmonary Arterial Hypertension
The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia
Treatment of O2 naïve patients with PAH will be included in this investigator-initiated trial (IIT) to assess efficacy and safety of oxygen substitution.
- Conditions
- Oxygen Deficiency, Pulmonary Arterial Hypertension, CTEPH
- Trial name
- SOPHA (NCT04207593)
- Testing
- Oxygen
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Hypertension, Pulmonary
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
The Study Hypothesis: Aggressive, upfront, dual therapy for treatment-naïve NYHA I/II/III PAH is superior to a traditional "step-up" approach. The study will evaluate: 1.
- Trial name
- NCT01305252
- Testing
- treprostinil inhalations, tadalafil
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil…
- Trial name
- TRITON (NCT02558231)
- Testing
- Macitentan, Tadalafil, Selexipag
- Where
- 58 sites in United States, Australia and 13 more
- Volunteers
- 247 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH
Pulmonary arterial hypertension (PAH) is progressive life limiting disease with a median survival of less than 3 years without treatment.
- Trial name
- RESPIRE (NCT03841344)
- Testing
- MRI
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with…
- Trial name
- PAH (NCT01457781)
- Testing
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Where
- 51 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study…
- Trial name
- NCT02279745
- Testing
- Ralinepag
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 45 people
- Sponsor
- United Therapeutics
Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
The BNP-PL is a multicenter, observational study in which patients are prospectively followed in order to investigate clinical course and management of pulmonary hypertension in Poland.
- Trial name
- BNP-PL (NCT03959748)
- Where
- Poland
- Volunteers
- 3,000 people
- Sponsor
- Polish Cardiology Association
Pulmonary Hypertension
Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pressure.
- Trial name
- NCT04055415
- Testing
- adipose derived mesenchymal stem cells, Conventional drug therapy（expectorant，bronchodilator）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Liaocheng People's Hospital
Pulmonary Hypertension
Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension
In this prospective case-control study, the investigators will evaluate the diagnostic performance of a novel electronic nose (E-nose) for the detection of Pulmonary Arterial Hypertension (PAH). This study is designed to: 1.
- Trial name
- SNOOPY2 (NCT02782026)
- Testing
- Exhaled Breath Olfactory Signature (Artificial Nose)
- Where
- France
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension
Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)
Patients with pulmonary arterial hypertension(PAH) suffer from chronic shortness of breath, and have impaired survival related to progressive right ventricular failure.
- Trial name
- MELISSA (NCT01181284)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension (PAH)
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a serious condition that puts strain on the right side of the heart. While oral medications can help, many patients with intermediate-risk PAH may not see enough improvement, and their…
- Trial name
- NCT07177703
- Testing
- Treprostinil
- Volunteers
- 32 people
- Sponsor
- Shanghai Zhongshan Hospital
Pulmonary Hypertension
PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature leading to elevated pulmonary pressure and right ventricular (RV) dysfunction with heart failure.
- Trial name
- PAHTCH (NCT01586156)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Pulmonary Arterial Hypertension
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01799473
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
HRV as a Marker of Treatment Response in PAH Arterial Hypertension
This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients
- Trial name
- NCT04451850
- Testing
- Noninvasive actigraphy monitor
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Cincinnati
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
In preparation for a future mechanistic study, investigators now propose to test the specific hypothesis that carnitine consumption is not reduced in PAH, that plasma carnitine levels are stable over time in PAH and that…
- Conditions
- Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases
- Trial name
- NCT04908397
- Testing
- L-carnitine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the…
- Trial name
- NCT05039086
- Testing
- PDE5 inhibitor, Endothelin Receptor Antagonists
- Where
- United States
- Volunteers
- 13,021 people
- Sponsor
- Brigham and Women's Hospital